Belite Bio, Inc
BLTE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001889109
In the last 90 days, Belite Bio, Inc insiders filed 0 open-market purchases and 5 sales; 80 institutions reported holding it in 13F filings for Q2 2026, worth $1.44B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.
Q3 2024 vs. Q2 2024
How the institutions holding Belite Bio, Inc changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 11 | 15 | +4 |
| Shares | 186.6K | 78.7K | −107.9K (−57.8%) |
| Value | $8.52M | $3.69M | −$4.83M (−56.7%) |
New holders (6)
Institutions that held Belite Bio, Inc at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 8,486 | $397.8K | 0.00% |
| Citadel Advisors LLC | 6,460 | $302.8K | 0.00% |
| XTX Topco Ltd | 5,394 | $252.9K | 0.02% |
| Cubist Systematic Strategies, LLC | 2,019 | $94.7K | 0.00% |
| Rhumbline Advisers | 1,435 | $67.3K | 0.00% |
| UBS Group AG | 128 | $6.00K | 0.00% |
Sold out (2)
Institutions that held Belite Bio, Inc at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Armistice Capital, LLC | 148,000 | $6.76M |
| HRT Financial LP | 5,409 | $247.0K |